Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| IL10 / IL10RA mAb | Monospecific antibody | Infectious and parasitic diseases | Immunodeficiencies | PCC | Global |
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| FCSm-010 | Mouse | Mouse IL-10 Detection Kit (Flow Cytometry Bead Assay) |
|
||
| FCSh-017 | Human | Human IL-10 Detection Kit (Flow Cytometry Bead Assay) |
|
||
| IL0-H82Q3 | Human | Biotinylated Human IL-10 Protein, His,Avitag™ |  |
|
|
| GMP-L10H25 | Human | GMP Human IL-10 Protein |  |
|
|
| CRS-B005 | Human | Human IL-10 ELISA Kit | |||
| IL0-C4248 | Cynomolgus | Cynomolgus IL-10 Protein, His Tag |  |
|
|
| IL0-H5219 | Human | Human IL-10 Protein, premium grade |  |
|
|
| CRS-A008 | Human | resDetect™ Human Interleukin-10 (IL-10) ELISA Kit (Residue Testing) | |||
| IL0-M4248 | Mouse | Mouse IL-10 Protein, His Tag |  |
|
|
| IL0-H4248 | Human | Human IL-10 Protein, His Tag |  |
|
|
Human IL-10, premium grade (Cat. No. IL0-H5219) Inhibits the IL‐6 secretion in RAW264.7 cell line. The specific activity of Human IL-10 Protein, premium grade＞1.00*10^7 IU/mg, which is calibrated against human IL- 10 WHO International Standard (NIBSC code: 93/722) (QC tested).
Immobilized Human IL-10, premium grade (Cat. No. IL0-H5219) at 5 μg/mL (100 μL/well) can bind Cynomolgus IL-10 R alpha Protein, Fc Tag (Cat. No. ILR-C5256) with a linear range of 0.1-2 ng/mL (QC tested).
The purity of Human IL-10, premium grade (Cat. No. IL0-H5219) is more than 90% and the molecular weight of this protein is around 32-42 kDa verified by SEC-MALS.
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Recombinant anti-InE monoclonal antibody | CmAb-(IL10)2 | Phase 1 Clinical | Dingfu Biotarget Co Ltd | Solid tumours | Details |
| KLS-2031 | KLS-2031 | Phase 2 Clinical | Kolon Life Science. Inc | Radiculopathy | Details |
| WP-1303 (worgpharma) | ATX-MS-1467; ATX-MS-01; M-2736; WP-1303; MSC-2358825A | Phase 2 Clinical | Apitope Technology | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis; Multiple Myeloma | Details |
This web search service is supported by Google Inc.
A-Z
